1127 related articles for article (PubMed ID: 32648313)
1. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
2. Potential strategies for combating COVID-19.
Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
[TBL] [Abstract][Full Text] [Related]
3. Covid-19: Time for a paradigm change.
Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
[No Abstract] [Full Text] [Related]
4. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
5. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
[TBL] [Abstract][Full Text] [Related]
6. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19.
Tanner T; Wahezi DM
Paediatr Respir Rev; 2020 Sep; 35():81-87. PubMed ID: 32792288
[TBL] [Abstract][Full Text] [Related]
7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
9. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
10. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
11. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
12. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
13. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Xi Y
Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
[No Abstract] [Full Text] [Related]
15. COVID-19: Immunology and treatment options.
Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic approaches to curtail COVID-19.
Owji H; Negahdaripour M; Hajighahramani N
Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
[TBL] [Abstract][Full Text] [Related]
17. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Abrams-Downey A; Saabiye J; Vidaurrazaga M
Eur Urol Focus; 2020 Sep; 6(5):1028-1031. PubMed ID: 32563675
[No Abstract] [Full Text] [Related]
18. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
19. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
20. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
Ahlawat S; Asha ; Sharma KK
Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
